297 related articles for article (PubMed ID: 1874739)
21. The interaction of spongistatin 1 with tubulin.
Bai R; Smith AB; Pettit GR; Hamel E
Arch Biochem Biophys; 2022 Sep; 727():109296. PubMed ID: 35594923
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
Towle MJ; Salvato KA; Budrow J; Wels BF; Kuznetsov G; Aalfs KK; Welsh S; Zheng W; Seletsky BM; Palme MH; Habgood GJ; Singer LA; Dipietro LV; Wang Y; Chen JJ; Quincy DA; Davis A; Yoshimatsu K; Kishi Y; Yu MJ; Littlefield BA
Cancer Res; 2001 Feb; 61(3):1013-21. PubMed ID: 11221827
[TBL] [Abstract][Full Text] [Related]
23. Interaction of phomopsin A with porcine brain tubulin. Inhibition of tubulin polymerization and binding at a rhizoxin binding site.
Li Y; Kobayashi H; Tokiwa Y; Hashimoto Y; Iwasaki S
Biochem Pharmacol; 1992 Jan; 43(2):219-24. PubMed ID: 1739410
[TBL] [Abstract][Full Text] [Related]
24. Derivatives of 5,6-diphenylpyridazin-3-one: synthetic antimitotic agents which interact with plant and mammalian tubulin at a new drug-binding site.
Batra JK; Powers LJ; Hess FD; Hamel E
Cancer Res; 1986 Apr; 46(4 Pt 2):1889-93. PubMed ID: 3948171
[TBL] [Abstract][Full Text] [Related]
25. Rhizoxin binding to tubulin at the maytansine-binding site.
Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y
Biochim Biophys Acta; 1987 Dec; 926(3):215-23. PubMed ID: 3120782
[TBL] [Abstract][Full Text] [Related]
26. Interaction of bovine brain tubulin with the 4(1H)-pyrizinone derivative IKP104, an antimitotic drug with a complex set of effects on the conformational stability of the tubulin molecule.
Luduena RF; Roach MC; Prasad V; Chaudhuri AR; Tomita I; Mizuhashi F; Murata K
Biochemistry; 1995 Dec; 34(48):15751-9. PubMed ID: 7495806
[TBL] [Abstract][Full Text] [Related]
27. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line.
Lobert S; Fahy J; Hill BT; Duflos A; Etievant C; Correia JJ
Biochemistry; 2000 Oct; 39(39):12053-62. PubMed ID: 11009620
[TBL] [Abstract][Full Text] [Related]
28. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
Bai R; Durso NA; Sackett DL; Hamel E
Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
[TBL] [Abstract][Full Text] [Related]
29. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
Mooberry SL; Taoka CR; Busquets L
Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
[TBL] [Abstract][Full Text] [Related]
30. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.
Jordan MA; Kamath K; Manna T; Okouneva T; Miller HP; Davis C; Littlefield BA; Wilson L
Mol Cancer Ther; 2005 Jul; 4(7):1086-95. PubMed ID: 16020666
[TBL] [Abstract][Full Text] [Related]
31. Microtubule-disrupting effects of gallium chloride in vitro.
Perchellet EM; Ladesich JB; Collery P; Perchellet JP
Anticancer Drugs; 1999 Jun; 10(5):477-88. PubMed ID: 10477168
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction.
Bai R; Schwartz RE; Kepler JA; Pettit GR; Hamel E
Cancer Res; 1996 Oct; 56(19):4398-406. PubMed ID: 8813133
[TBL] [Abstract][Full Text] [Related]
33. A quantitative evaluation of the effects of inhibitors of tubulin assembly on polymerization induced by discodermolide, epothilone B, and paclitaxel.
Dabydeen DA; Florence GJ; Paterson I; Hamel E
Cancer Chemother Pharmacol; 2004 May; 53(5):397-403. PubMed ID: 15060743
[TBL] [Abstract][Full Text] [Related]
34. Interaction of cryptophycin 1 with tubulin and microtubules.
Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
[TBL] [Abstract][Full Text] [Related]
35. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
Lobert S; Vulevic B; Correia JJ
Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
[TBL] [Abstract][Full Text] [Related]
36. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
37. LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.
de Arruda M; Cocchiaro CA; Nelson CM; Grinnell CM; Janssen B; Haupt A; Barlozzari T
Cancer Res; 1995 Jul; 55(14):3085-92. PubMed ID: 7606731
[TBL] [Abstract][Full Text] [Related]
38. Structural insight into the inhibition of tubulin by vinca domain peptide ligands.
Cormier A; Marchand M; Ravelli RB; Knossow M; Gigant B
EMBO Rep; 2008 Nov; 9(11):1101-6. PubMed ID: 18787557
[TBL] [Abstract][Full Text] [Related]
39. Effect of phomopsin A on the alkylation of tubulin.
Ludueña RF; Roach MC; Prasad V; Lacey E
Biochem Pharmacol; 1990 May; 39(10):1603-8. PubMed ID: 2337418
[TBL] [Abstract][Full Text] [Related]
40. Interaction of rhizoxin with bovine brain tubulin.
Sullivan AS; Prasad V; Roach MC; Takahashi M; Iwasaki S; Ludueña RF
Cancer Res; 1990 Jul; 50(14):4277-80. PubMed ID: 2364385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
